Therapeutic Gene Editing Firm Epic Bio Launches With $55M Series A Financing
The company said the funding will help it advance its preclinical pipeline of epigenetic modulatory therapies, and it anticipates its first clinical trial in 2023.
Mass General, CRISPR Therapeutics to Develop Cancer Therapies
The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
CRISPR Therapeutics, Neon Therapeutics Enter Research Collaboration
The two companies plan to combine their respective gene editing and neoantigen discover technologies in order to develop new T cell therapies for cancer patients.
CRISPR Therapeutics Licenses Cell Engineering Platform From MaxCyte
The firm will use MaxCyte's cell transfection platform to edit hematopoietic stem cells with CRISPR/Cas9 in hemoglobinopathy and SCID.
UC can still salvage its CRISPR IP rights after last week's decision, but a long-shot appeal in federal court is the only possibility for total victory.